- Home
- RCKT vs VNDA Comparison
RCKT vs VNDA Comparison
Compare RCKT & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RCKT
- VNDA
- Stock Information
- Founded
- RCKT 1999
- VNDA 2002
- Country
- RCKT United States
- VNDA United States
- Employees
- RCKT N/A
- VNDA N/A
- Industry
- RCKT Biotechnology: Pharmaceutical Preparations
- VNDA Biotechnology: Pharmaceutical Preparations
- Sector
- RCKT Health Care
- VNDA Health Care
- Exchange
- RCKT Nasdaq
- VNDA Nasdaq
- Market Cap
- RCKT 326.4M
- VNDA 261.7M
- IPO Year
- RCKT N/A
- VNDA 2006
- Fundamental
- Price
- RCKT $2.70
- VNDA $4.55
- Analyst Decision
- RCKT Buy
- VNDA Strong Buy
- Analyst Count
- RCKT 13
- VNDA 3
- Target Price
- RCKT $18.50
- VNDA $15.33
- AVG Volume (30 Days)
- RCKT 8.4M
- VNDA 370.7K
- Earning Date
- RCKT 08-04-2025
- VNDA 07-30-2025
- Dividend Yield
- RCKT N/A
- VNDA N/A
- EPS Growth
- RCKT N/A
- VNDA N/A
- EPS
- RCKT N/A
- VNDA N/A
- Revenue
- RCKT N/A
- VNDA $201,351,000.00
- Revenue This Year
- RCKT N/A
- VNDA $16.86
- Revenue Next Year
- RCKT N/A
- VNDA $39.78
- P/E Ratio
- RCKT N/A
- VNDA N/A
- Revenue Growth
- RCKT N/A
- VNDA 13.37
- 52 Week Low
- RCKT $2.19
- VNDA $3.81
- 52 Week High
- RCKT $26.98
- VNDA $6.37
- Technical
- Relative Strength Index (RSI)
- RCKT 32.09
- VNDA 53.76
- Support Level
- RCKT $2.66
- VNDA $4.49
- Resistance Level
- RCKT $3.33
- VNDA $4.63
- Average True Range (ATR)
- RCKT 0.28
- VNDA 0.14
- MACD
- RCKT 0.09
- VNDA 0.00
- Stochastic Oscillator
- RCKT 26.59
- VNDA 50.00
About RCKT Rocket Pharmaceuticals Inc.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. The Company has one reportable segment related to R&D and commercial readiness of its gene therapies.
About VNDA Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.